Dose per serving from products
623 products in our catalogue print how much Huperzine A a serving holds.
Most common: 50 mcg to 100 mcg, 25% of 623 products.
| Dose per serving | Products |
|---|---|
| 5 mcg or less | 5 |
| 5 mcg to 10 mcg | 89 |
| 10 mcg to 25 mcg | 38 |
| 25 mcg to 50 mcg | 105 |
| 50 mcg to 100 mcg | 157 |
| 100 mcg to 250 mcg | 155 |
| 250 mcg to 500 mcg | 31 |
| 500 mcg to 1 mg | 1 |
| 1 mg to 2.5 mg | 2 |
| 2.5 mg to 5 mg | 16 |
| over 5 mg | 24 |
Dose per serving from research
7 study groups in 5 studies say how much Huperzine A participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 50 mcg to 100 mcg, 43% of 7 study groups.
| Daily dose | Study groups |
|---|---|
| 50 mcg to 100 mcg | 3 |
| 100 mcg to 250 mcg | 1 |
| 250 mcg to 500 mcg | 2 |
| 500 mcg to 1 mg | 1 |
Benefit Evidence
Research sources
Memory (8)
- Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students
PubMed ID: 10678121
Double‑blind adolescent trial reported large, statistically significant memory‑quotient gains vs placebo.
- Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease
PubMed ID: 8701750
Randomized placebo‑controlled trial (8 weeks) showed greater improvement in memory/cognition/behavior than placebo.
- [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]
PubMed ID: 12181083
Large multicenter RCT with significant ADAS‑Cog and MMSE improvements — strong direct evidence for memory/cognition benefit.
- Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer's disease
PubMed ID: 30839402
Pre–post study in AD patients on huperzine A noted cognitive and task performance improvements vs baseline.
- Treatment with Huperzine A improves cognition in vascular dementia patients
PubMed ID: 21833673
Randomized vascular dementia trial reported improved MMSE — direct memory benefit.
- A phase II trial of huperzine A in mild to moderate Alzheimer disease
PubMed ID: 21502597
Large randomized trial with no benefit at low dose but modest, dose‑dependent cognitive signal at higher dose.
- Huperzine-A in capsules and tablets for treating patients with Alzheimer disease
PubMed ID: 10678137
Small randomized trial in AD showed cognitive score improvements vs baseline/placebo over 60 days.
- [Drug evaluation of huperzine A in the treatment of senile memory disorders]
PubMed ID: 1781288
Large uncontrolled cohort reported Wechsler memory improvements in elderly memory‑disordered patients.
Learning (5)
- [Drug evaluation of huperzine A in the treatment of senile memory disorders]
PubMed ID: 1781288
Older uncontrolled study reported memory scale gains that may reflect improved learning.
- Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer's disease
PubMed ID: 30839402
Task‑switching improvements after 8 weeks suggest gains in processing speed (pre–post design).
- [Effect of huperzine A on cerebral cholinesterase and acetylcholine in elderly patients during recovery from general anesthesia]
PubMed ID: 17121726
Central cholinergic augmentation plausibly supports processing speed, though direct measures were not reported.
- [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]
PubMed ID: 12181083
Improvements in cognitive scales in AD suggest better capacity for acquiring/retaining new information.
- Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students
PubMed ID: 10678121
Students showed improved memory quotient and better Chinese language scores after 4 weeks — direct learning outcome.
Mental clarity (4)
- Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease
PubMed ID: 8701750
Randomized trial with 8‑week symptomatic cognitive/behavioral improvements implying clearer thinking.
- Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students
PubMed ID: 10678121
Double‑blind student trial showed notable memory and school performance gains that map to clearer cognition.
- [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]
PubMed ID: 12181083
Large RCT showed clinically meaningful global cognitive gains (ADAS‑Cog/MMSE) consistent with improved mental clarity.
- [Effect of huperzine A on cerebral cholinesterase and acetylcholine in elderly patients during recovery from general anesthesia]
PubMed ID: 17121726
CSF acetylcholine increase supports mechanistic basis for clearer cognition (small perioperative study).
Focus & concentration (4)
- Treatment with Huperzine A improves cognition in vascular dementia patients
PubMed ID: 21833673
Vascular dementia RCT improvements in MMSE/ADL suggest better attentional functioning/concentration.
- [Effect of huperzine A on cerebral cholinesterase and acetylcholine in elderly patients during recovery from general anesthesia]
PubMed ID: 17121726
Direct biochemical evidence of increased CSF acetylcholine and ChE inhibition that underpins attentional enhancement.
- [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]
PubMed ID: 12181083
Large RCT cognitive gains are consistent with improved concentration/attentional control in mild–moderate AD.
- Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer's disease
PubMed ID: 30839402
Improved task‑switching performance after 8 weeks suggests faster executive processing (non‑randomized).
Brain health (3)
- Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease
PubMed ID: 8701750
Randomized AD trial with symptomatic benefit supports huperzine A as a therapeutic for age‑related cognitive decline.
- [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]
PubMed ID: 12181083
Large RCT in mild–moderate AD with significant cognitive and functional improvements — strong aging‑brain support.
- Treatment with Huperzine A improves cognition in vascular dementia patients
PubMed ID: 21833673
Randomized vascular dementia trial showed cognitive and ADL improvements in elderly patients.
Productivity (3)
- Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students
PubMed ID: 10678121
Students had improved memory and language scores — consistent with better academic productivity in the short term.
- [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]
PubMed ID: 12181083
Global cognitive benefits could include processing/response speed improvements though not directly measured.
- [Effect of huperzine A on cerebral cholinesterase and acetylcholine in elderly patients during recovery from general anesthesia]
PubMed ID: 17121726
CSF cholinergic changes plausibly translate to faster sensorimotor/processing speed; direct RT data lacking.
Endurance (2)
- Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease
PubMed ID: 8701750
8‑week trial showed symptomatic improvements suggesting some gain in cognitive endurance/consolidation.
- [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]
PubMed ID: 12181083
Sustained cognitive and functional improvements over 12 weeks suggest improved cognitive endurance in AD.
Alertness (2)
- [Effect of huperzine A on cerebral cholinesterase and acetylcholine in elderly patients during recovery from general anesthesia]
PubMed ID: 17121726
Direct increase in CSF acetylcholine and ChE inhibition — strong mechanistic support for cholinergic-mediated alertness.
- [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]
PubMed ID: 12181083
Clinical cognitive improvement in AD may include improved alertness/awareness as part of global gains.
Energy & Fatigue (1)
- [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]
PubMed ID: 12181083
Improvements in ADL and global cognition over 12 weeks suggest better sustained mental functioning; direct energy measures absent.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Huperzine A
Search all1220 products whose verified label declares Huperzine A — not every bottle that mentions it in a title.